Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

Abstract Background Patients with cancer are at high risk for severe courses of COVID-19. Based on (pre-)clinical data suggesting a potential protective effect due to the immunomodulating properties of azithromycin, we have initiated a prospective randomized trial. Methods This randomized, single-ce...

Descripció completa

Dades bibliogràfiques

Autors principals:	Maximilian J. Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Pröll, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C. Puhr, Angelika M. Starzer, Ariane Steindl, Sabine Eberl, Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W. Prager, Wolfgang W. Lamm, Anna S. Berghoff, Barbara Kiesewetter, Markus Zeitlinger, Matthias Preusser, Markus Raderer
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2023-02-01
Col·lecció:	Infectious Agents and Cancer
Matèries:	COVID-19 SARS-CoV-2 Azithromycin Prophylactic treatment Oncology
Accés en línia:	https://doi.org/10.1186/s13027-023-00487-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!